Provention will wait for FDA to ‘opine’ on new data after teplizumab rejection, eyes Q4 for further talks

Provention will wait for FDA to ‘opine’ on new data after teplizumab rejection, eyes Q4 for further talks https://ift.tt/3nyyOLn